Regulatory Science and Policy Subcommittee
The AACR established the Regulatory Science and Policy Subcommittee in March of 2011 to support the FDA’s endeavor to modernize the regulatory process and accommodate the fast pace of innovation in science and technology. The subcommittee leads the AACR’s efforts to facilitate scientific exchange among stakeholders from academia, industry, advocacy, and government to unleash the true potential of regulatory science to serve patients. In order for the latest research to inform regulators, regulatory guidelines and regulatory policy, regulators must keep abreast with developments in cancer research. Scientists also benefit from an understanding of the regulatory process, which can facilitate their own research programs and speed the translation of discoveries into new and improved interventions.
The subcommittee is dedicated to bringing together and providing an open forum for stakeholder engagement. It is also actively engaged in the development and implementation of programmatic and policy initiatives to improve the development, evaluation and regulation of cancer drugs, biologics and diagnostics.
Subcommittee Members

Kenneth C. Anderson, MD, FAACR
Subcommittee Chairperson
Program Director and Chief, Division of Hematologic Neoplasia, Kraft Family Professor of Medicine
Harvard Medical School, Dana-Farber Cancer Institute
Boston, Massachusetts
Peter C. Adamson, MD, PhD
Professor Emeritus of Pediatrics and Pharmacology
Perelman School of Medicine
Philadelphia, Pennsylvania
Chris Boshoff, MD, PhD
Chief Scientific Officer and President, Research and Development
Pfizer, Inc.
New York, New York
Dushen Chetty, PhD
Global Head of Oncology Development
Novartis Oncology
East Hanover, New Jersey
Marcia Cruz-Correa, MD, PhD
Executive Director, University of Puerto Rico Comprehensive Cancer Center
Professor, University of Puerto Rico Medical Sciences
San Juan, Puerto Rico
Christopher R. Flowers, MD
Division Head of Cancer Medicine
MD Anderson
Houston, Texas
Susan M. Galbraith, MBBCh, PhD
Executive Vice-President, Oncology R&D
AstraZeneca
Cambridge, England
Levi A. Garraway, MD, PhD
Head of Global Product Development, Chief Medical Officer
F. Hoffman-LaRoche Ltd.
South San Francisco, California
Daniel F. Hayes, MD, FASCO
Stuart B. Padnos Professor of Breast Cancer Research
University of Michigan Rogel Cancer Center
Ann Arbor, Michigan
Jane A. Healy, MD, PhD
Vice President, Head of Oncology Early Development
Merck Research Laboratories
Rahway, New Jersey
Roy S. Herbst, MD, PhD
Ensign Professor of Medicine, Associate
Director for Translational Research
Yale Cancer Center
New Haven, Connecticut
David M. Hyman, MD
Chief Medical Officer
Eli Lilly and Company
Stamford, Connecticut
Pasi A. Jänne, MD, PhD
Director, Lowe Center for Thoracic Oncology
Scientific Director, Belfer Institute for Applied Cancer Science
Dana-Farber Cancer Institute
Boston, Massachusetts
Chitkala Kalidas, PhD
Senior Vice President and Global Head Environment, Social and Government
Bayer
Hillsborough, New Jersey
Ramon Kemp, DVM, PhD
Vice President and Head, Oncology Early Development
GlaxoSmithKline
Philadelphia, Pennsylvania
Peter F. Lebowitz, MD, PhD
Senior Vice President, Global Therapeutic Area Head, Oncology
Janssen Research and Development, LLC
Wayne, Pennsylvania
Rebecca Mancini, MS
Executive Director, Global Regulatory Affairs, Oncology
Gilead Sciences
Parsippany, New Jersey
Elaine R. Mardis, PhD
Co-executive Director, Institute for Genomic Medicine
Nationwide Children’s Hospital
Columbus, Ohio
Amy C. Peterson, MD
Executive Vice President, Product Development and Medical Affairs
Chief Medical Officer
Exelixis
San Francisco, California
Thomas Powles, MBBS, MRCP, MD
Director, Clinical Professor of Genitourinary Oncology
Barts Cancer Institute
London, England
David M. Reese, MD
Executive Vice President and Chief Technology Officer
Amgen Inc.
Los Angeles, California
Howard I. Scher, MD
Chief of Genitourinary Oncology
Memorial Sloan Kettering Cancer Center
New York, New York
Ellen V. Sigal, PhD
Chairperson and Founder
Friends of Cancer Research
Washington, D.C.
Diane M. Simeone, MD
Director, Moores Cancer Center
University of California at San Diego
San Diego, California
AACR Staff Contact
Rukiya Umoja, PharmD, RPh
Assistant Director, Regulatory Science and Policy
Email